In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

PerkinElmer purchases ViaCell for $283mm

Executive Summary

PerkinElmer will buy umbilical cord blood banking company ViaCell in a tender offer valued at about $283mm. PerkinElmer will pay $7.25 for each outstanding ViaCell share, a 54% premium to the pre-announcement market average. (Immediately following the after-hours news release of the deal, ViaCell's stock climbed as much as 50% higher than its previous close.)
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Intra-Biotech Deal
    • Payment Includes Cash

Related Companies